

Online Data Supplement

Respiratory function and CT abnormalities among survivors of COVID-19 pneumonia – a nationwide follow-up study

Gisli Thor Axelsson^{1,2}, Arnljotur Bjorn Halldorsson³, Helgi Mar Jonsson³, Elias Eythorsson², Sigridur Erla Sigurdardottir⁴, Hronn Hardardottir^{1,4}, Gunnar Gudmundsson^{1,4}, Sif Hansdottir⁴

¹University of Iceland, Faculty of Medicine, Reykjavik, Iceland;

²Department of Internal Medicine, Landspítali University Hospital, Reykjavik, Iceland;

³Department of Medical Imaging, Landspítali University Hospital, Reykjavik, Iceland;

⁴Department of Respiratory Medicine and Sleep, Landspítali University Hospital, Reykjavik, Iceland.




Figure S1 – CT score at follow-up stratified by existence of radiologic findings

Box plots of the distributions of CT scores at follow-up stratified by the existence of reticular changes and subpleural banding on imaging at follow-up. Dashes indicate differences between indicated groups, tested with t-tests.

*** refers to $P < 0.001$

Table S1 – Associations of treatment level with pulmonary outcomes at follow-up using complete case analysis

	Models using absolute values		Models using % of predicted		
	Beta (95% CI)	P-value	Beta (95% CI)	P-value	
6MWT (meters)					
Inpatient	-36 (-73 to 0.95)	0.058	-4.5 (-10 to 1.2)	0.12	
ICU	-92 (-137 to -47)	0.0001	-13 (-20 to -6.5)	0.0002	
FVC (litres)					
Inpatient	0.04 (-0.27 to 0.36)	0.78	-1.8 (-8.4 to 4.7)	0.59	
ICU	-0.39 (-0.78 to -0.005)	0.049	-8.1 (-16 to 0.04)	0.053	
FEV₁ (litres)					
Inpatient	0.07 (-0.15 to 0.29)	0.53	-0.77 (-7.4 to 5.9)	0.82	
ICU	-0.12 (-0.40 to 0.15)	0.38	-3.0 (-11 to 5.1)	0.47	
FEV₁/FVC					
Inpatient	1.0 (-1.7 to 3.6)	0.49	-	-	
ICU	5.0 (1.6 to 8.3)	0.004	-	-	
DL_{co} (mmol/(min·kPa))					
Inpatient	-0.45 (-1.0 to 0.14)	0.14	-8.8 (-15 to -3.0)	0.003	
ICU	-1.8 (-2.5 to -1.1)	<0.0001	-22 (-29 to -14)	<0.0001	
Saturation after 6MWT (%)					
Inpatient	-0.14 (-1.3 to 1.0)	0.82	-	-	
ICU	-2.1 (-3.5 to -0.71)	0.004	-	-	
mMRC					
Inpatient	1.0 (0.08 to 2.0)	0.03	-	-	
ICU	0.68 (-0.46 to 1.8)	0.24	-	-	

Results from regression models of treatment level, adjusted for age, sex, BMI and history of smoking, type 2 diabetes, any lung disease and hypertension, with the specified outcome (its absolute value on the left and, when applicable, a percentage of a predicted value on the right). Models are done using complete-case analysis, omitting participants with missing predictor, outcome or covariate data. Models are linear models, except for mMRC modelled with proportional odds models. mMRC was modelled using three categories (1,2, and 3 or more). Age is modelled using a restricted cubic spline with four knots.

Table S2 – Associations of CT-score at follow-up with pulmonary outcomes using complete case analysis

	Models using raw values		Models using % of predicted	
	Beta (95% CI)	P-value	Beta (95% CI)	P-value
6MWT (metres)				
CT score	-4.9 (-7.2 to -2.7)	<0.0001	-0.75 (-1.1 to -0.41)	<0.0001
FVC (litres)				
CT score	-0.04 (-0.06 to -0.02)	0.0002	-0.44 (-0.83 to -0.04)	0.031
FEV₁ (litres)				
CT score	-0.02 (-0.03 to -0.003)	0.018	-0.09 (-0.49 to 0.31)	0.67
FEV₁/FVC (%)				
CT score	0.34 (0.19 to 0.50)	<0.0001	-	-
DL_{co} (mmol/(min·kPa))				
CT score	-0.12 (-0.15 to -0.08)	<0.0001	-1.2 (-1.5 to -0.81)	<0.0001
Saturation after 6MWT (%)				
CT score	-0.11 (-0.18 to -0.04)	0.003	-	-
mMRC				
CT score	0.01 (-0.04 to 0.07)	0.66	-	-

Results from regression models of CT score, adjusted for age, sex, BMI and history of smoking, type 2 diabetes, any lung disease and hypertension, with the specified outcome (its absolute value on the left and, when applicable, a percentage of a predicted value on the right). Models are done using complete-case analysis, omitting participants with missing predictor, outcome or covariate data. Models are linear models, except for mMRC modelled with proportional odds models. mMRC was modelled using three categories (1,2, and 3 or more). Age is modelled using a restricted cubic spline with four knots.